WC
BMRN icon

Woodstock Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

Woodstock Corp’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Hold
8,176
– – 0.04% 121
2026
Q1 		$462K Hold
8,176
– – 0.04% 119
2025
Q4 		$486K Hold
8,176
– – 0.04% 116
2025
Q3 		$443K Buy
+8,176
New +$468K 0.04% 123

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Woodstock Corp's BMRN Position: Q2 2026 in Review

Woodstock Corp held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 8,176 shares worth $468K. The position accounts for 0.04% of the portfolio, ranked #121.

Woodstock Corp first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. The position peaked at $486K in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Woodstock Corp held 8,176 shares of BioMarin Pharmaceuticals worth $468K as of Q2 2026.
  • Woodstock Corp left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.04% of Woodstock Corp's portfolio in Q2 2026, its #121 holding.
  • Woodstock Corp first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Woodstock Corp's BioMarin Pharmaceuticals position peaked at $486K in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Woodstock Corp's 13F filing for Q2 2026, filed 13 Jul 2026.